QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 verrica-pharmaceuticals-to-present-phase-2-data-on-vp-315-for-basal-cell-carcinoma-at-sitc-2025-annual-meeting

Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medic...

 verrica-pharmas-development-partner-torii-pharma-receives-approval-from-japanese-mhlw-for-ycanth-for-treatment-of-molluscum-contagiosum

– Approval triggers $10 million cash milestone payment to Verrica –– YCANTH® approval in Japan addresses significant unmet need...

 verrica-pharmaceuticals-q2-adj-eps-025-beats-007-estimate-sales-12702m-beat-4367m-estimate

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate ...

 verrica-reports-record-13434-ycanth-applicator-units-dispensed-in-q2-2025-marking-328-sequential-growth

– Company reports sequential quarterly growth of 32.8% over Q1 2025 with a record 13,434 YCANTH Dispensed applicator units in Q...

 verrica-pharmaceuticals-announces-second-amendment-to-its-existing-collaboration-and-licensing-agreement-with-torii-pharmaceutical-to-initiate-a-global-pivotal-phase-3-trial-of-verricas-ycanth-for-common-warts

Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule.V...

 needham-reiterates-hold-on-verrica-pharmaceuticalsto-hold

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Hold.

 verrica-pharmaceuticals-q1-adj-eps-008-beats-010-estimate-sales-344m-beat-251m-estimate

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION